Related Experiment Video
Updated: Aug 13, 2026
10:12
Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human
Dale J Kempf1, Jeffrey F Waring, David C Morfitt
1Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064, USA. dale.kempf@abbott.com
Antimicrobial Agents and Chemotherapy
|January 27, 2006
Abstract:
A practical preclinical model for the hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors has been developed. Indinavir and atazanavir produced significant hyperbilirubinemia, whereas amprenavir, the negative control, was indistinguishable from the ritonavir booster dose. This model was used to disqualify an exploratory protease inhibitor from development.
